Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: Recommendations of an international panel

Archives of Internal Medicine

Volumn 158, Issue 9, 1998, Pages 957-969

  Whitley, Richard J ^a   Jacobson, Mark A ^b   Friedberg, Dorothy N ^c   Holland, Gary N ^d   Jabs, Douglas A ^e   Dieterich, Douglas T ^c   David Hardy, W ^d   Polis, Michael A ^f   Deutsch, Thomas A ^g   Feinberg, Judith ^h   Spector, Stephen A ⁱ   Walmsley, Sharon ^j   Lawrence Drew, W ^b   Powderly, William G ^k   Griffiths, Paul D ^l   Benson, Constance A ^g,m   Kessler, Harold A ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g RUSH MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l ROYAL FREE HOSPITAL   (United Kingdom)

^m UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CIDOFOVIR; DIDANOSINE; FOSCARNET; GANCICLOVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; PROBENECID; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD TOXICITY; COLITIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; OPHTHALMOSCOPY; ORAL DRUG ADMINISTRATION; PNEUMONIA; POLYRADICULITIS; PRIORITY JOURNAL; RETINITIS; TREATMENT CONTRAINDICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; FOSCARNET; GANCICLOVIR; HUMANS; LUNG DISEASES; NERVOUS SYSTEM DISEASES; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RETINITIS;

EID: 0032507777     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.9.957     Document Type: Article

References (112)

1. Whitcup SM, Fortin E, Nussenblatt RB, Polis MA, Muccioli C, Belfort R Jr. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA. 1997;277:1519.
2. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease inhibitor treatment in patients with AIDS. Am J Ophthalmol. 1997;124:199-205.
3. Torriani FJ, Macdonald JC, Karevellas M, Freeman WR. Lack of progression after discontinuation of maintenance therapy (MT) for cytomegalovirus retinitis (CMVR) in AIDS patients responding to highly active antiretroviral therapy (HAART). In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract I-33.
4. Tural C, Sirera G, Andreu D, et al. Long lasting remission of cytomegalovirus retinitis without maintenance therapy in HIV+ patients. In: Program and abstracts of the 37th Interscience Con- ference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract I-36.
5. Centers for Disease Control and Prevention. The prevention of AIDS-related opportunistic infections: updated guidelines. MMWR CDC Surveill Summ. 1997;46:1-55.
6. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18:421.
7. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cyto megalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575-582.
8. Shinkai M, Bozzette S, Powderly W, Frame P, Spector S. Utility of urine and leukocyte cultures and plasma DMA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis. 1997;175:302-308.
9. Dodt KK, Jacobsen PH, Hofman B, et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS. 1997;11:F21-F28.
10. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus (CMV) viremia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS. 1997;11:889-893.
11. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996;334:1491-1497.
12. Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J infect Dis. 1992;166:1223-1227.
13. McCann J, Margolis T, Wong M, et al. A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis. Am J Ophthalmol. 1995;120:219-226.
14. Freeman W, Wiley C, Gross J, et al. Endoretinal biopsy in immunosuppressed and healthy patients with retinitis. Ophthalmology. 1989;96:1559-1565.
15. Holland GN, Buhles WCJ, Mastre B, Kaplan HJ, for the UCLA CMV Retinopathy Study Group. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch Ophthalmol. 1989;107:1759-1766.
16. Holland GN, Pepose JS, Pettit TH, et al. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology. 1983;90:859-873.
17. Baldassano V, Dunn JP, Feinberg J, Jabs D. Cytomegalovirus retinitis and low CD4+T-lymphocyte counts. N Engl J Med. 1995;333:670.
18. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus. Am J Ophthalmol. 1993;116:713-720.
19. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
20. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial 4: visual outcomes. Ophthalmology. 1994;101:1250-1261.
21. Davis J, Serfass M, Lai M, et al. Silicone oil in repair of retinal detachments caused by necrotizing retinitis in HIV infection. Arch Ophthalmol. 1995;113:1401-1409.
22. Holland GN, Levinson RD, Jacobson MA, and the AIDS Clinical Trials Group Protocol 915 Team. Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. Am J Ophthalmol. 1995;119:576-586.
23. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Assessment of cytomegalovirus retinitis: clinical evaluation vs centralized grading of fundus photographs. Arch Ophthalmol. 1996;114:791-805.
24. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326:213-220.
25. Stanley HD, Charlebois E, Harb G, Jacobson MA, Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:272-278.
26. Lalezari J, Friedberg D, Bisset J, Giordano M, Hardy D, Robinson C. A comparison of the safety and efficacy of 3G, 4.5G, and 6G doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis. In: Program and abstracts of the XI International Conference on AIDS; July 7-10, 1996; Vancouver, British Columbia. Abstract Th.B.305.
27. Grossniklaus HE, Frank KE, Tomsak RL. Cytomegalovirus retinitis and optic neuritis in acquired immune deficiency syndrome. Ophthalmology. 1987;94:1601-1604.
28. Martin D, Kuppermann B, Wolitz R, Palestine C, Robinson C. Combined oral ganciclovir (GCV) and intravitreal GCV implant for treatment of patients with cytomegalovirus (CMV) retinitis: a randomized, controlled study. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1,1997; Toronto, Ontario. Abstract LB-9.
29. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD, for the Ganciclovir Implant Study Group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med. 1997;337:83-90.
30. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS. 1995;9:471-477.
31. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 1995;333:615-620.
32. Squires KE, Stempien MJ, Shadman A, Buhles WC. Oral ganciclovir versus intravenous ganciclovir maintenance therapy for cytomegalovirus retinitis in patients with AIDS. In: Program and abstracts of the First National Conference on Human Retroviruses; December 12-16, 1993; Washington, DC. Abstract 540.
33. Specter SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis. 1993;168:557-563.
34. Laskin AJM, Cederberg D, Mills J, Eron LJ, Mildvan D, Spector SA. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med. 1987;83:201-207.
35. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med. 1995;155:65-74.
36. Hardy D, Spector S, Polsky B, et al. Combination ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1994;13(suppl 2):S34-S40.
37. Jacobson MA, Causey DM, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis. 1993;168:444-448.
38. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol. 1994;112:1531-1539.
39. Lalezari JP, Stagg RJ, Kuppermann BD. et al. Intravenous cidofovir for peripheral CMV retinitis in patients with AIDS. Ann Intern Med. 1997;126:257-263.
40. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med. 1997;126:264-274.
41. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol. 1997;115:733-737.
42. Diaz-Lopis M, Espana E, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol. 1994;78:120-124.
43. Cantrill HL, Henry K, Melroe H, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology. 1988;96:367-374.
44. Ussery FM, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology. 1988;95:640-648.
45. Cochereau-Massin I, LeHoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991;98:1348-1353.
46. Hodge WG, Lalonde RG, Sampalis J, Deschenes J. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcomes. J Infect Dis. 1996;174:393-396.
47. Polsky B, Hurwitz S, Chuang EL, et al. Intravitreal ganciclovir salvage therapy for cytomegalovirus retinitis in AIDS: AIDS Clinical Trials Group protocol 085. J Infect Dis. 1997;1:70-74.
48. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993;168:1506-1509.
49. Arevalo JF, Gonzales C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis. 1995;172:951-956.
50. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Studies of Ocular Complications of AIDS Fos- carnet-Ganciclovir Cytomegalovirus Retinitis Trial, I: rationale, design, and methods. Control Clin Trials. 1992;13:22-39.
51. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious Cytomegalovirus intection. J Infect Dis. 1991;163:716-719.
52. Jabs DA, Dunn JP, Enger C, et al. Cytomegalovirus retinitis and viral resistance: prevalence of resistance at diagnosis, 1994. Arch Ophthalmol. 1996;114:809-814.
53. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with either foscarnet or ganciclovir. J Infect Dis. 1997;176:50-58.
54. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol. 1996;114:23-33.
55. Erice A, Chou S, Biron KK, et al. Progressive disease due to ganciclovir-resistant Cytomegalovirus in immunocompromised patients. N Engl J Med. 1989;320:289-293.
56. Lalezari JP, Holland GN, Kramer F, et al. Cidofovir for relapsing Cytomegalovirus retinitis: a randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing Cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. In press.
57. Freitas VR, Fraser-Smith EB, Matthew TR. Increased efficacy of ganciclovir in combination with foscarnet against Cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 1989;12:205-212.
58. Manischewitz JF, Quinnan GVJ, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on Cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990;34:373-375.
59. Marx JL, Kapusta MA, Patel SS, et al. Use of the ganciclovir implant in the treatment of recurrent Cytomegalovirus retinitis. Arch Ophthalmol. 1996;114:815-820.
60. Kirsch LS, Arevalo JF, DeClercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of Cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1995;119:466-476.
61. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS: a preliminary report. Ann Intern Med. 1996;125:98-103.
62. Dieterich DT, Wilcox CM. Diagnosis and treatment of esophageal diseases associated with HIV infection. Am J Gastroenterol. 1996;91:2265-2269.
63. Dieterich DT, Poles MA, Lew EA. Gastrointestinal manifestations of HIV disease. In: Broder S, Merigan T, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore, Md: Williams & Wilkins; 1994:541-554.
64. Chachoua A, Dieterich DT, Krasinski K, et al. '9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) in the treatment of Cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med. 1987;107:133.
65. Frank D, Raicht RF. Intestinal perforation associated with Cytomegalovirus infection in patients with acquired immunodeficiency syn- drome. Am J Gastroenterol. 1984;79:201.
66. Lew E, Dieterich DT, Poles MA, Scholes J. Gastrointestinal emergencies in the patient with AIDS. Crit Care Clin. 1995;11:531-560.
67. Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr Hum Retrovirol. 1991;4(suppl 1):S29-S35.
68. Dieterich DT. Ganciclovir treatment of cytomegalovirus gastrointestinal disease in patients with AIDS. In: Spector S, ed. Ganciclovir Therapy for Cytomegalovirus Infection. New York, NY: Marcel Dekker Inc; 1991:129-144.
69. Dieterich DT, Kotler DP, Busch DF, et al. Ganciclovir treatment of Cytomegalovirus colitis in AIDS: a randomized double-blind, placebo controlled multicenter study. J Infect Dis. 1993;167:278-282.
70. Poles MA, Dieterich DT. Foscarnet treatment of CMV gastrointestinal disease: a pharmacokinetic pilot study. Antimicrob Agents Chemother. 1997;41:1226-1230.
71. Dieterich DT, Chachoua A, Lefleur F, et al. Ganciclovir treatment of gastrointestinal infections caused by CMV in patients with AIDS. Rev Infect Dis. 1988;10(suppl 3):S532-S537.
72. Simon D, Weiss LM, Brandt LJ. Treatment options for AIDS-related esophageal and diarrhea disorders. Am J Gastroenterol. 1993;87:274-282.
73. Nelson MR, Connoly GM, Hawkis DA, et al. Foscarnet in the treatment of Cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. Am J Gastroenterol. 1991;86:876-881.
74. Dieterich DT, Poles MA, Lew E, et al. Foscarnet treatment of Cytomegalovirus gastrointestinal infections in AIDS patients who have failed ganciclovir induction. Am J Gastroentrol. 1993;88:542-546.
75. Dieterich DT, Poles MA, Lew E. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis. 1993;167:1184-1188.
76. McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis. 1995;20:747-754.
77. Olney RK. Acute lumbosacral polyradiculopathy in acquired immunodeficiency syndrome: experience in 23 patients. Ann Neurol. 1994;35:53-58.
78. Miller RF, Fox JD, Thomas P, et al. Acute lumbosacral polyradiculopathy due to Cytomegalovirus in advanced HIV disease: CSF findings in 17 patients. J Neurol Neurosurg Psychiatry. 1996;61:456-460.
79. Granter SR, Doolittle MH, Renshaw AA. Predominance of neutrophils in the cerebrospinal fluid of AIDS patients with Cytomegalovirus radiculopathy. Am J Clin Pathol. 1996;105:364-366.
80. Kalayjian RC, Cohen ML, Bonomo RA, Flanigan TP. Cytomegalovirus ventriculoencephalitis in AIDS: a syndrome with distinct clinical and pathological features. Medicine (Baltimore). 1993;72:67-77.
81. Holland NR, Power C, Mathews VP, Glass JD, Forman M, McArthur JC. Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS). Neurology. 1994;44:507-514.
82. Arribas JR, Storch GA, Clifford DB, Tselis AC. Cytomegalovirus encephalitis. Ann Intern Med. 1996;125:577-587.
83. Shinkai M, Spector SA. Quantitation of human cytomegalovirus (HCMV) DNA in cerebrospinal fluid by competitive PCR in AIDS patients with different HCMV central nervous system diseases. Scand J Infect Dis. 1995;27:559-561.
84. Arribas JR, Clifford DB, Fichtenbaum CJ, Commins Dt, Powderly WG, Storch GA. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnostic utility of semi-quantitative PCR. J Infect Dis. 1995;172:527-531.
85. Cohen BA. Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. Neurology. 1996;46:444-450.
86. Berman SM, Kim RC. The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. Am J Med. 1994;96:415-419.
87. Wolf DG, Lee DJ, Spector SA. Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother. 1995;39 (supp1 11):2552-2554.
88. Smith IL, Shinkai M, Freeman WR, Spector SA. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential viral isolates. J infect Dis. 1996;173:1481-1484.
89. Drew WL, Mintz L, Miner RC, et al. Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis. 1981;143:188-192.
90. Stover DE, White DA, Romano PA, Gellene RA, Robeson WA. Spectrum of pulmonary disease associated with the acquired immune deficiency syndrome. Am J Med. 1985;78:429-437.
91. Miles PR, Baughman RP, Linnemann CC Jr. Cytomegalovirus in the bronchoalveolar lavage fluid of patients with AIDS. Chest. 1990;97:1072-1076.
92. Jacobson MA, Mills J, Rush J, et al. Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. Am Rev Respir Dis. 1991;144:6-9.
93. Bozzette SA, Arcia J, Bartok AE, et al. Impact of Pneumocystis carinii and cytomegalovirus on the course and outcome of atypical pneumonia in advanced human immunodeficiency virus disease. J Infect Dis. 1992;165:93-98.
94. Gardner TD, Youle M, Hanson PJ, Griffiths PJ, Collins JV, Gazzard BG. Diagnosis, treatment, and outcome of pneumonia in the acquired immune deficiency syndrome. J Infect Dis. 1989;18:111-117.
95. Bower M, Barton SE, Nelson MR, et al. The significance of the detection of cytomegalovirus in the bronchoalveolar lavage fluid in AIDS patients with pneumonia. AIDS. 1990;4:317-320.
96. Meduri GU, Stover DE, Greeno RA, Nash T, Zaman MB. Bilateral bronchoalveolar lavage in the diagnosis of opportunistic pulmonary infections. Chest. 1991;100:1272-1276.
97. Broaddus C, Dake MD, Stulberg MS, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the ac- quired immunodeficiency syndrome. Ann Intern Med. 1985;102:747-752.
98. Rodriguez-Barradas MC, Stool E, Musher DM, et al. Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. Clin Infect Dis. 1996;23:76-81.
99. Suffredini AF, Ognibene FP, Lack EE, et al. Non-specific interstitial pneumonitis: a common cause of pulmonary disease in the acquired immuno-deficiency syndrome. Ann Intern Med. 1987;107:7-13.
100. Polis M. Systemic treatment: advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med. 1996;125:126-136.
101. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119:924-935.
102. McKenzie R, Travis WD, Dolan SA, et al. The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases. Medicine (Baltimore). 1991;70:326-343.
103. Monforte AD, Vago L, Lazzarin A, et al. AIDS-defining diseases in 250 HIV-infected patients: a comparative study of clinical and autopsy diagnoses. AIDS. 1992;6:1159-1164.
104. Klatt EC, Shibata D. Cytomegalovirus infection in the acquired immunodeficiency syndrome: clinical and autopsy findings. Arch Pathol Lab Med. 1988;112:540-544.
105. Pillay D, Lipman MC, Lee CA, Johnson MA, Griffiths PD, McLaughlin JE. A clinico-pathological audit of opportunistic viral infections in HIV-infected patients. AIDS. 1993;7:969-974.
106. Webster A, McLaughlin JE, Johnson MA, Emery VC, Griffiths PD. Use of the polymerase chain reaction to detect genomes of human immunodeficiency virus and cytomegalovirus in postmortem tissues. J Med Virol. 1995;47:23-28.
107. Pulakhandam U, Dincsoy HP. Cytomegalovirus adrenalitis and adrenal insufficiency in AIDS. Am J Clin Pathol. 1990;93:651-656.
108. Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD. The effect of CMV infection on progression of immunodeficiency virus disease in a cohort of hemophilic men followed for up to 13 years from seroconversion. Epidemiol Infect. 1995;114:361-372.
109. Bowen EF, Wilson P, Cope A, et al. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS. 1996;10:1515-1520.
110. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995;39:882-886.
111. Jabs DA, Bartlett JG. AIDS and ophthalmology: a period of transition. Am J Ophthalmol. 1997;124:227-233.
112. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.